Find Nusinersen Sodium manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

9RELATED EXCIPIENT COMPANIES

8EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Gtpl9416, Isis396443
Molecular Formula
C234H340N61O128P17S17
Molecular Weight
7127  g/mol
InChI Key
WWFDJIVIDXJAQR-FFWSQMGZSA-N

Nusinersen Sodium
1 2D Structure

Nusinersen Sodium

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
2.1.2 InChI
InChI=1S/C234H340N61O128P17S17/c1-106-66-278(224(308)261-178(106)235)205-162(356-50-32-338-14)144(119(391-205)79-373-425(320,442)407-143-117(77-296)389-204(161(143)355-49-31-337-13)282-70-110(5)193(298)271-228(282)312)410-431(326,448)383-89-129-154(172(366-60-42-348-24)215(401-129)289-99-254-135-182(239)246-95-250-186(135)289)419-436(331,453)379-81-121-145(163(357-51-33-339-15)206(393-121)279-67-107(2)179(236)262-225(279)309)408-426(321,443)375-83-123-149(167(361-55-37-343-19)210(395-123)284-72-112(7)195(300)273-230(284)314)413-429(324,446)378-86-125-150(168(362-56-38-344-20)211(397-125)285-73-113(8)196(301)274-231(285)315)414-430(325,447)377-85-124-148(166(360-54-36-342-18)209(396-124)283-71-111(6)194(299)272-229(283)313)412-428(323,445)374-80-120-147(165(359-53-35-341-17)208(392-120)281-69-109(4)181(238)264-227(281)311)411-432(327,449)384-90-130-155(173(367-61-43-349-25)216(402-130)290-100-255-136-183(240)247-96-251-187(136)290)420-437(332,454)381-87-127-152(170(364-58-40-346-22)213(399-127)287-75-115(10)198(303)276-233(287)317)415-433(328,450)385-91-131-157(175(369-63-45-351-27)218(403-131)292-102-257-138-185(242)249-98-253-189(138)292)422-440(335,457)386-92-132-156(174(368-62-44-350-26)217(404-132)291-101-256-137-184(241)248-97-252-188(137)291)421-438(333,455)382-88-128-153(171(365-59-41-347-23)214(400-128)288-76-116(11)199(304)277-234(288)318)417-435(330,452)388-94-134-159(177(371-65-47-353-29)220(406-134)295-105-260-141-192(295)267-223(245)270-202(141)307)423-439(334,456)380-82-122-146(164(358-52-34-340-16)207(394-122)280-68-108(3)180(237)263-226(280)310)409-427(322,444)376-84-126-151(169(363-57-39-345-21)212(398-126)286-74-114(9)197(302)275-232(286)316)416-434(329,451)387-93-133-158(176(370-64-46-352-28)219(405-133)294-104-259-140-191(294)266-222(244)269-201(140)306)418-424(319,441)372-78-118-142(297)160(354-48-30-336-12)203(390-118)293-103-258-139-190(293)265-221(243)268-200(139)305/h66-76,95-105,117-134,142-177,203-220,296-297H,30-65,77-94H2,1-29H3,(H,319,441)(H,320,442)(H,321,443)(H,322,444)(H,323,445)(H,324,446)(H,325,447)(H,326,448)(H,327,449)(H,328,450)(H,329,451)(H,330,452)(H,331,453)(H,332,454)(H,333,455)(H,334,456)(H,335,457)(H2,235,261,308)(H2,236,262,309)(H2,237,263,310)(H2,238,264,311)(H2,239,246,250)(H2,240,247,251)(H2,241,248,252)(H2,242,249,253)(H,271,298,312)(H,272,299,313)(H,273,300,314)(H,274,301,315)(H,275,302,316)(H,276,303,317)(H,277,304,318)(H3,243,265,268,305)(H3,244,266,269,306)(H3,245,267,270,307)/t117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?/m1/s1
2.1.3 InChI Key
WWFDJIVIDXJAQR-FFWSQMGZSA-N
2.1.4 Canonical SMILES
CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)OP(=S)(O)OCC3C(C(C(O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OCC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OCC8C(C(C(O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=O)(OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)S)OCCOC
2.1.5 Isomeric SMILES
CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)S)OCCOC
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. Gtpl9416

2. Isis396443

2.3 Create Date
2017-01-30
3 Chemical and Physical Properties
Molecular Weight 7127 g/mol
Molecular Formula C234H340N61O128P17S17
XLogP3-14.4
Hydrogen Bond Donor Count40
Hydrogen Bond Acceptor Count167
Rotatable Bond Count176
Exact Mass7124.2829700 g/mol
Monoisotopic Mass7122.2762603 g/mol
Topological Polar Surface Area2820 Ų
Heavy Atom Count457
Formal Charge0
Complexity19100
Isotope Atom Count0
Defined Atom Stereocenter Count72
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameSPINRAZA
Active IngredientNUSINERSEN SODIUM
CompanyBIOGEN IDEC (Application Number: N209531. Patents: 6166197, 6210892, 7101993, 7838657, 8110560, 8361977, 8980853)

API SUPPLIERS

read-more
read-more

01

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

02

Pharmathen SA

Greece

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Pharmathen

03

Anhui Ribobay Pharmaceutical Co.,L...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Ribobay-Company-Banner

04

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

06

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Ionis Pharmaceuticals

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Ionis Pharmaceuticals

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

08

Jiangsu Sinopep Allsino Biopharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Shanghai Sinuotides Biopharmaceutica...

Country

USDMF

arrow
Cophex
Not Confirmed

01

Shanghai Sinuotides Biopharmaceutica...

Country
arrow
Cophex
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41707

Submission : 2025-03-28

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Nusinersen

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

02

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Nusinersen

About the Company : Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle manage...

Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle management of complex pharmaceutical technologies & generic formulations. With a portfolio of over 100 products, Pharmathen serves over 250 clients across 80 countries. It’s pipeline includes advanced long-acting injectables, sustained-release formulations & preservative-free ophthalmics manufactured in USFDA & EU-approved facilities. Pharmathen’s core technology platforms, including microspheres, nanosuspensions & nanogels, are used to develop long-acting therapies.
Pharmathen

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

Flag China
Digital Content Digital Content

Nusinersen

About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...

Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuzhou, within the Nanjing metropolitan area, Ribobay Pharmaceutical specializes in the therapeutic oligonucleotides CXO field. This strategic focus aligns with General Biol's broader expansion plans for its CXO business, making Ribobay a crucial component of the company's ventures in this domain.
Ribobay-Company-Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Nusinersen

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
Omgene Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Nusinersen Sodium

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

06

BPI Europe
Not Confirmed
arrow
arrow
BPI Europe
Not Confirmed

Nusinersen Sodium

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and efficient manufacturing technologies, Sinopep ensures global compliance with advanced process development. Their CRDMO services span peptides, oligonucleotides, and synthetic conjugates, making them a trusted partner worldwide in pharmaceutical and healthcare solutions.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1688322600,"product":"NUSINERSEN (FREE OF COST)","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"HANGZHOU APEXTIDE BIOMEDICAL","supplierCountry":"CHINA","foreign_port":"NA","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"850","totalValueFC":"1717.8","currency":"USD","unitRateINR":"70592.6","date":"03-Jul-2023","totalValueINR":"141185.17","totalValueInUsd":"1717.8","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734633000,"product":"NUSINERSEN NUSINERSEN","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"HANGZHOU APEXTIDE BIOMEDICAL","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"1.32","unit":"GMS","unitRateFc":"2221","totalValueFC":"2965.5","currency":"USD","unitRateINR":"190891.7","date":"20-Dec-2024","totalValueINR":"251977.03","totalValueInUsd":"2965.5","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"7350163","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"TECHNOLOGY CO., LTD BUILDING 14, YINHAI KECHUANG CENTER NO.501 FUCHENG ROAD, XIASHA STREET CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734633000,"product":"NUSINERSEN NUSINERSEN","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"HANGZHOU APEXTIDE BIOMEDICAL","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"CIPLA","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"103","unit":"GMS","unitRateFc":"2366.5","totalValueFC":"246563.7","currency":"USD","unitRateINR":"203400.7","date":"20-Dec-2024","totalValueINR":"20950269.53","totalValueInUsd":"246563.7","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"7350163","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"TECHNOLOGY CO., LTD BUILDING 14, YINHAI KECHUANG CENTER NO.501 FUCHENG ROAD, XIASHA STREET CHINA","customerAddress":"MUMBAI CENTRAL,"}]
03-Jul-2023
20-Dec-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 23, 2025

blank

01

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

January 23, 2025

blank

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 10, 2024

blank

02

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

September 10, 2024

blank

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 03, 2024

blank

03

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

June 03, 2024

blank

Details:

Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Lantesens

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 14, 2024

blank

04

Generium

Russia
arrow
AACR Annual meeting
Not Confirmed

Generium

Russia
arrow
AACR Annual meeting
Not Confirmed

Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Product Name : Lantesens

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

May 14, 2024

blank

Details:

Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 09, 2024

blank

05

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

April 09, 2024

blank

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Royalty Pharma

Deal Size: $1,125.0 million Upfront Cash: $500.0 million

Deal Type: Agreement September 01, 2023

blank

06

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : $500.0 million

September 01, 2023

blank

Details:

SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Biogen

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 27, 2023

blank

07

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

June 27, 2023

blank

Details:

SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Biogen

Deal Size: $51.0 million Upfront Cash: $10.0 million

Deal Type: Collaboration April 01, 2023

blank

08

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : $10.0 million

April 01, 2023

blank

Details:

RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA (nusinersen) treatment following gene therapy was well-tolerated.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 15, 2022

blank

09

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA (nusinersen) treatment following gene therapy was well-tolerated.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

June 15, 2022

blank

Details:

The results from NURTURE, a study in infants treated in presymptomatic stage of SMA, demonstrate that early and sustained treatment with SPINRAZA for up to 5.7 years, helped participants to maintain and make progressive gains in motor function.


Lead Product(s): Nusinersen Sodium

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 14, 2022

blank

10

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : The results from NURTURE, a study in infants treated in presymptomatic stage of SMA, demonstrate that early and sustained treatment with SPINRAZA for up to 5.7 years, helped participants to maintain and make progressive gains in motor function.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

March 14, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Nusinersen

Brand Name :

Dosage Form : Solution For Injection

Dosage Strength : 12MG/5ML

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

02

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

05

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

06

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

07

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

08

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

09

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

10

Biogen

U.S.A
ISPE Europe
Not Confirmed
arrow

Biogen

U.S.A
arrow
ISPE Europe
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Nusinersen

Brand Name :

Dosage Form : Solution For Injection

Dosage Strength : 12MG/5ML

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

01

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Packaging :

Regulatory Info : USA

Nusinersen

Dosage : Solution For Injection

Dosage Strength : 12MG/5ML

Brand Name :

Approval Date :

Application Number :

Registration Country : Greece

Pharmathen
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Controlled & Modified Release

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
AAPS National Biotech
Not Confirmed
arrow
AAPS National Biotech
Not Confirmed

Company :

Nusinersen Sodium/PF

Drug Cost (USD) : 2,632,872

Year : 2022

Prescribers :

Prescriptions : 18

blank

02

arrow
AAPS National Biotech
Not Confirmed
arrow
AAPS National Biotech
Not Confirmed

Company :

Nusinersen Sodium/PF

Drug Cost (USD) : 2,782,478

Year : 2021

Prescribers :

Prescriptions : 19

blank

03

arrow
AAPS National Biotech
Not Confirmed
arrow
AAPS National Biotech
Not Confirmed

Company :

Nusinersen Sodium/PF

Drug Cost (USD) : 5,622,217

Year : 2020

Prescribers : 17

Prescriptions : 40

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Spinraza

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Disorders

Currency : USD

2020 Revenue in Millions : 2,052

2019 Revenue in Millions : 2,097

Growth (%) : -2

blank

02

Brand Name : SPINRAZA royalties

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : SPINRAZA royalties

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Disorders

Currency : USD

2020 Revenue in Millions : 287

2019 Revenue in Millions : 293

Growth (%) : -2

blank

03

Brand Name : Spinraza

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Disorders

Currency : USD

2021 Revenue in Millions : 1,905

2020 Revenue in Millions : 2,052

Growth (%) : -7

blank

04

Brand Name : SPINRAZA royalties

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : SPINRAZA royalties

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Disorders

Currency : USD

2021 Revenue in Millions : 268

2020 Revenue in Millions : 287

Growth (%) : -7

blank

05

Brand Name : Spinraza Royalties

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza Royalties

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2022 Revenue in Millions : 242

2021 Revenue in Millions : 268

Growth (%) : -10

blank

06

Brand Name : Spinraza

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2022 Revenue in Millions : 1,794

2021 Revenue in Millions : 1,905

Growth (%) : -6

blank

07

Brand Name : Spinraza Royalties

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza Royalties

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2023 Revenue in Millions : 240

2022 Revenue in Millions : 242

Growth (%) : -1

blank

08

Brand Name : Spinraza

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2023 Revenue in Millions : 1,741

2022 Revenue in Millions : 1,794

Growth (%) : -3

blank

09

Brand Name : Spinraza

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Spinal Muscular Atrophy

Currency : USD

2017 Revenue in Millions : 884

2016 Revenue in Millions : 5

Growth (%) : 19,111

blank

10

Brand Name : Spinraza

Nusinersen

arrow
AAPS National Biotech
Not Confirmed

Brand Name : Spinraza

U.S.A
arrow
AAPS National Biotech
Not Confirmed

Nusinersen

Main Therapeutic Indication : Spinal Muscular Atrophy

Currency : USD

2018 Revenue in Millions : 1,724

2017 Revenue in Millions : 884

Growth (%) : 95%

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 10436802

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1944

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-11

blank

02

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 12013403

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1942

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-04

blank

03

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 10436802

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1943

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-11

blank

04

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 9717750

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1942

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-06-17

blank

05

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 12013403

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1943

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-04

blank

06

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 10436802

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1941

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-11

blank

07

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 9717750

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-2094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-06-17

blank

08

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 12013403

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-1944

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-03-04

blank

09

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 10436802

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-2093

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-11

blank

10

arrow
AACR Annual meeting
Not Confirmed

BIOGEN IDEC

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

US Patent Number : 9717750

Drug Substance Claim :

Drug Product Claim :

Application Number : 209531

Patent Use Code : U-2093

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-06-17

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for / Nusinersen API manufacturers, exporters & distributors?

Nusinersen manufacturers, exporters & distributors 1

59

PharmaCompass offers a list of Nusinersen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nusinersen manufacturer or Nusinersen supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nusinersen manufacturer or Nusinersen supplier.

PharmaCompass also assists you with knowing the Nusinersen API Price utilized in the formulation of products. Nusinersen API Price is not always fixed or binding as the Nusinersen Price is obtained through a variety of data sources. The Nusinersen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Nusinersen

Synonyms

Gtpl9416, Isis396443

Spinraza Manufacturers

A Spinraza manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Spinraza, including repackagers and relabelers. The FDA regulates Spinraza manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Spinraza API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Spinraza manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Spinraza Suppliers

A Spinraza supplier is an individual or a company that provides Spinraza active pharmaceutical ingredient (API) or Spinraza finished formulations upon request. The Spinraza suppliers may include Spinraza API manufacturers, exporters, distributors and traders.

click here to find a list of Spinraza suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Spinraza USDMF

A Spinraza DMF (Drug Master File) is a document detailing the whole manufacturing process of Spinraza active pharmaceutical ingredient (API) in detail. Different forms of Spinraza DMFs exist exist since differing nations have different regulations, such as Spinraza USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Spinraza DMF submitted to regulatory agencies in the US is known as a USDMF. Spinraza USDMF includes data on Spinraza's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Spinraza USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Spinraza suppliers with USDMF on PharmaCompass.

Spinraza NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Spinraza as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Spinraza API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Spinraza as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Spinraza and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Spinraza NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Spinraza suppliers with NDC on PharmaCompass.

Spinraza GMP

Spinraza Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Spinraza GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Spinraza GMP manufacturer or Spinraza GMP API supplier for your needs.

Spinraza CoA

A Spinraza CoA (Certificate of Analysis) is a formal document that attests to Spinraza's compliance with Spinraza specifications and serves as a tool for batch-level quality control.

Spinraza CoA mostly includes findings from lab analyses of a specific batch. For each Spinraza CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Spinraza may be tested according to a variety of international standards, such as European Pharmacopoeia (Spinraza EP), Spinraza JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Spinraza USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty